




RealRate

# PHARMACEUTICAL 2017

## PUMA BIOTECHNOLOGY INC. Rank 162 of 292





RealRate

# PHARMACEUTICAL 2017

## PUMA BIOTECHNOLOGY INC. Rank 162 of 292



The relative strengths and weaknesses of PUMA BIOTECHNOLOGY INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA BIOTECHNOLOGY INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of PUMA BIOTECHNOLOGY INC. is the variable Research and Development, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 57%, being 55% points above the market average of 2.9%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 236,474           |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 37,461            |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 11,163            |
| Other Compr. Net Income                     | 134               |
| Other Expenses                              | 0                 |
| Other Liabilities                           | 5,505             |
| Other Net Income                            | 585               |
| Other Revenues                              | 0                 |
| Property and Equipment                      | 5,153             |
| Research and Development                    | 222,798           |
| Selling, General and Administrative Expense | 53,798            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 252,790           |
| Liabilities              | 42,966            |
| Expenses                 | 276,596           |
| Revenues                 | 0                 |
| Stockholders Equity      | 209,824           |
| Net Income               | -276,011          |
| Comprehensive Net Income | -275,944          |
| Economic Capital Ratio   | 57%               |